Leadman released its 2026 interim report. Total operating revenue was 152 million yuan, down 5.31% year-on-year. Net loss attributable to the parent company was 7.113 million yuan, a decrease of 2.8679 million yuan compared with the same period last year, with the loss widening year-on-year. Net cash inflow from operating activities was 9.2498 million yuan, up 947.07% year-on-year. The company's asset-liability ratio was 5.24%, gross margin was 43.44%, return on equity was negative 0.44%, and diluted earnings per share was negative 0.01 yuan. The number of shareholders was 25,000, and the top ten shareholders held 50.87% of the total share capital.
Beijing Leadman Biochemistry Co LtdNet loss widened year-on-year in interim report